Pelthos Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
| For the Nine months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities: | ||
| Net loss | $(21,655) | $(6,029) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Accretion of interest for royalty obligations | 1,316 | — |
| Depreciation of property and equipment | 389 | — |
| Amortization of intangibles | 679 | — |
| Amortization of debt discount | 259 | 616 |
| Lease amortization expense | 74 | — |
| Stock-based compensation | 3,662 | 1,269 |
| Inventory write-off | 792 | — |
| Gain on default judgment | — | (363) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (7,940) | — |
| Inventory | 1,385 | — |
| Prepaid expenses | (1,411) | (890) |
| Operating lease right-of-use assets | 243 | — |
| Accounts payable | 4,031 | 558 |
| Accrued expenses | 2,689 | (283) |
| Operating lease liabilities | (189) | — |
| Deferred revenue | (294) | — |
| Deferred income tax | (465) | — |
| Other assets and liabilities | 97 | — |
| Net cash used in operating activities | (16,338) | (5,122) |
| Cash flow from investing activities: | ||
| Acquisition of LNHC, Inc. | 2,761 | |
| Net cash provided by investing activities | 2,761 | — |
| Cash flow from financing activities: | ||
| Proceeds from PIPE, net | 27,384 | — |
| Proceeds from stock option exercises | 85 | — |
| Proceeds from loan payable, net of debt discount | 693 | 690 |
| Payment of loan payable, net of debt discount | (845) | (215) |
| Common stock issued for cash | — | 5,972 |
| Rescission of common stock | — | (166) |
| Net cash provided by financing activities | 27,317 | 6,281 |
| Net increase in cash and cash equivalents | 13,740 | 1,159 |
| Cash, cash equivalents and restricted cash as of beginning of period | 513 | 96 |
| Cash, cash equivalents and restricted cash as of end of period | $14,253 | $1,255 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE****NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (CONTINUED)
| Reconciliation to condensed consolidated balance sheets: | ||
|---|---|---|
| Cash and cash equivalents | $14,203 | $513 |
| Restricted cash | 50 | — |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $14,253 | $513 |
| Supplemental cash flow information: | ||
|---|---|---|
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $19 | $— |
| Supplemental non-cash investing and financing activities: | ||
| PIPE proceeds allocated to accounts payable | $1,776 | $— |
| PIPE proceeds allocated to debt payable | $20,340 | $— |
| PIPE proceeds allocated to fees | $600 | $— |
| Royalty agreement liability reclassified from additional paid in capital | $10,821 | $— |
| Debt discount from common stock issued for extension of bridge loan | $— | $448 |
| Shares issued for payment of account payable or for services | $50 | $7 |
| Conversion of notes to common stock | $737 | $1,363 |
| Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock | $— | $2,153 |
| Account payable and accrued expenses converted to notes | $— | $1,455 |
| Account payable and accrued expenses converted to notes - related party | $— | $132 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.